IDH1 and central nervous system cancer: Earlier studies revealed widespread IDH1 mutations at Arg132, an active site of the enzyme, in WHO grade II and III (referred to as lower-grade) glioma and in WHO grade IV secondary glioblastoma [9,10,11].